clinical trial · NCT06265688
First In Human Study of CX-2051 in Advanced Solid Tumors
Solid Tumor, AdultCX-2051Bevacizumab
brief summary
The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.
started
Apr 2, 2024
primary completion
Nov 30, 2027
completion
Mar 31, 2029
last updated
Mar 25, 2026
detailed description
The study is comprised of 2 parts. Part 1 involves CX-2051 dose escalation to identify the maximum tolerated dose (MTD) of CX-2051 as monotherapy and as combination therapy (CX-2051 combined with bevacizumab). Part 2 (dose expansion) will further assess safety and tolerability as well as preliminarily assess antitumor activity of CX-2051 as monotherapy and/or combination therapy in indication-specific expansion cohorts.
official title
An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol